Levodopa infusion pump
We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations.
– We are leading the inclusion internationally of a trial with sublingual Apomorphine.
Our Unit leads the inclusion of randomized patients comparing sublingual apomorphine versus the classic subcutaneous apomorphine for the indication in blocking off.
← Volver Evaluation of an inhibitor of the LRRK 2 gene in Parkinson’s patients. Oral…
← Volver Trial on LRRK2 mutation in Parkinson’s disease is about to be completed. Our…
← Volver Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in…
← Volver The new formulation of inhaled levodopa, Inbrija, has been approved for marketing in…
← Volver The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks,…
← Volver An intranasal levodopa has been authorized in the US to treat off blockages,…
← Volver Our Unit has achieved to be activated in this outstanding project and so…
← Volver We appreciate the great effort made by our patients to contribute to the…
Más idiomas
ES / EN / CAT son las versiones oficiales revisadas.
